NASDAQ (NYSE:NASDAQ) shares fell as investors scrambled to digest news about a new US approval of a new antibiotic for Crohn’s disease, while other stocks were hit by the announcement of a merger between Pfizer and Regeneron Pharmaceuticals.The Nasdaq composite fell 3.8%, or $2.43, to 1,938.26, while the S&P 500 index, which tracks the broadest […]

Continue Reading...